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Abstract
Previous studies have shown that rats withdrawn from long-term
treatment with dopamine receptor blockers exhibit dopaminergic
supersensitivity, which can be behaviorally evaluated by enhanced
general activity observed in an open-field. Recently, it has been
reported that co-treatment with the non-benzodiazepine anxiolytic
buspirone attenuates the development of haloperidol-induced dopa-
minergic supersensitivity measured by open-field behavior of rats.
The aims of the present study were: 1) to determine, as previously
reported for rats, if mice withdrawn from long-term neuroleptic
treatment would also develop dopaminergic supersensitivity using
open-field behavior as an experimental paradigm, and 2) to examine if
acute buspirone administration would attenuate the expression of this
behavioral dopaminergic supersensitivity. Withdrawal from long-
term haloperidol treatment (2.5 mg/kg, once daily, for 20 days)
induced a significant (30%) increase in ambulation frequency (i.e.,
number of squares crossed in 5-min observation sessions) but did not
modify rearing frequency or immobility duration in 3-month-old
EPM-M1 male mice observed in the open-field apparatus. Acute
intraperitoneal injection of buspirone (3.0 and 10 but not 1.0 mg/kg,
12-13 animals per group) 30 min before open-field exposure abol-
ished the increase in locomotion frequency induced by haloperidol
withdrawal. These data suggest that the open-field behavior of mice
can be used to detect dopaminergic supersensitivity, whose expression
is abolished by acute buspirone administration.
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In rats, abrupt withdrawal from long-term
dopamine receptor blockers such as halo-
peridol (1-3), bromopride (4), metoclopra-
mide (5) or sulpiride (6) enhances general
activity observed in an open-field. This ef-
fect has been considered to be a consequence
of the development of supersensitivity of
central dopaminergic pathways. Indeed, be-
havioral supersensitivity is thought to result
from receptor site proliferation in mesolim-
bic and striatal brain tissues in response to
chronic dopamine receptor blockade (7,8).
From a clinical point of view, dopaminergic
supersensitivity has been proposed as a pos-
sible contributing factor to the development
of tardive dyskinesia, a serious adverse mo-
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tor effect of prolonged administration of an-
tipsychotic drugs that is characterized by
abnormal involuntary repetitive movements
of the face and limbs that are purposeless in
nature (for a review, see Ref. 9).
The effects of the non-benzodiazepine
anxiolytic buspirone have been studied both
on dopaminergic supersensitivity measured
by rat behavior in an open-field and on tar-
dive dyskinesia in humans. The similar re-
sults obtained in these two experimental situ-
ations have corroborated the alleged rela-
tionship between this movement disorder
and dopaminergic supersensitivity. Indeed,
although buspirone has high affinity for do-
paminergic-binding sites (10) and reduces
yawning and stereotypy induced by the do-
paminergic agonist apomorphine (11), its
withdrawal after repeated treatment fails to
enhance the open-field behavior of rats (12).
Buspirone has not been demonstrated to pro-
duce tardive dyskinesia in humans (13). On
the contrary, Moss et al. (14) showed that
repeated buspirone treatment decreased the
severity of tardive dyskinesia, consistent with
the inhibitory effects of buspirone co-treat-
ment on the development of haloperidol-
induced dopaminergic supersensitivity meas-
ured by open-field behavior (12).
The aims of the present study were two-
fold: first, to determine if, as previously
reported for rats, mice withdrawn from long-
term haloperidol treatment would develop
dopaminergic supersensitivity evaluated by
open-field behavior, and second, to investi-
gate the effects of acute buspirone adminis-
tration on the expression of this behavioral
phenomenon.
Two experiments were performed using
3-month-old male EPM-M1 mice, an out-
bred stock. In the first experiment, animals
were randomly divided into five groups, i.e.,
one control and four experimental groups of
12-13 mice each. Mice of the experimental
groups were injected intraperitoneally (ip)
with 2.5 mg/kg haloperidol (HAL) daily for
20 days and animals of the control group
received the same number of injections of
0.9% NaCl (SAL) by the same route. Sev-
enty-two hours after the last haloperidol or
0.9% NaCl injection, the animals received
an ip injection of 0.9% NaCl or 1.0, 3.0 or 10
mg/kg buspirone (BUS). Thus, the treatments
of the five groups of animals were as fol-
lows: SAL-SAL, HAL-SAL, HAL-BUS1,
HAL-BUS3 and HAL-BUS10. Thirty min-
utes later, mice were placed individually in
the open-field arena and behavioral param-
eters (i.e., ambulation and rearing frequen-
cies and immobility duration) were observed
for 5 min as proposed by Conceição and
Frussa-Filho (11). Hand-operated counters
and stopwatches were employed to score
ambulation (the number of squares crossed)
and rearing frequencies, and immobility du-
ration (time of complete absence of paw
movements), respectively.
In the second experiment, animals were
randomly divided into four groups, i.e., one
control and three experimental groups of 12
animals each. Mice of the experimental
groups were acutely treated with 1.0, 3.0 or
10.0 mg/kg buspirone (ip) and animals of the
control group received 0.9% NaCl. Thirty
minutes later, mice were placed individually
in the open-field arena for behavioral quan-
tification as described above.
An experienced observer who was blind
to the identity of the animals quantified the
open-field behavior. Analysis of variance
(ANOVA) followed by the Duncan post hoc
test was used to study the open-field data.
The level of significance was set at P<0.05.
As shown in Figure 1A, withdrawal from
haloperidol treatment significantly increased
ambulation frequency of HAL-SAL mice
compared to SAL-SAL mice (F(4,59) = 3.71;
P<0.05). Acute buspirone administration
abolished this effect. Indeed, the ambulation
frequencies presented by mice of the HAL-
BUS3 and HAL-BUS10 groups were sig-
nificantly lower than that exhibited by the
HAL-SAL group. In addition, the ambula-
tion frequencies of animals of the HAL-
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BUS1, HAL-BUS3 and HAL-BUS10 groups
were not different from those presented by
the SAL-SAL group. The duration of immo-
bility presented by the HAL-BUS3 and HAL-
BUS10 groups was significantly higher than
that presented by the HAL-SAL group
(F(4,59) = 2.57; P<0.05). Finally, no exper-
imental group presented differences in rear-
ing frequency or immobility duration when
compared to the SAL-SAL group.
As can be seen in Table 1, acute buspi-
rone administration was also able to inhibit
open-field behavior in mice that did not re-
ceive haloperidol before. Indeed, at the doses
of 3.0 and 10.0 mg/kg, buspirone induced
significant decreases in ambulation (F(3,44)
= 12.09; P<0.01) and rearing (F(3,44) =
22.40; P<0.01) frequencies and a significant
increase in immobility duration (F(3,44) =
17.43; P<0.01).
The major findings of the present study
were that: 1) as previously reported for rats,
mice withdrawn from long-term treatment
with haloperidol develop dopaminergic su-
persensitivity measured by open-field be-
havior; 2) this behavioral supersensitivity
was detected by the locomotion frequency
parameter but not by two other open-field
behavioral parameters, i.e., rearing frequency
and immobility duration, and 3) the expres-
sion of this haloperidol-induced behavioral
supersensitivity was abolished by acute bus-
pirone administration.
As far as we know, this is the first demon-
stration that, like rats, mice develop dopa-
minergic supersensitivity as evaluated by
spontaneous open-field behavior. This ani-
mal model may be of particular use since the
hypothesis of dopamine supersensitivity has
dominated the conceptual approaches to
studying tardive dyskinesia over the last de-
cades (15) and behavioral supersensitivity is
still a useful animal model of tardive dyski-
nesia (for a review, see Ref. 9).
Within this context, the demonstration
that mice also can be used as experimental
subjects of this behavior paradigm raises the
Table 1. Effect of acute administration of different doses of buspirone on open-field
behavior.
Groups Behavioral parameters
Ambulation frequency Rearing frequency Immobility duration
Saline 117.67 ± 5.92 40.25 ± 2.76 16.00 ± 3.62
Buspirone (1 mg/kg) 111.92 ± 6.74 34.67 ± 3.66 16.83 ± 6.11
Buspirone (3 mg/kg) 78.67 ± 8.05* 18.75 ± 3.10* 75.50 ± 12.55*
Buspirone (10 mg/kg) 57.58 ± 11.02* 10.67 ± 1.75* 109.00 ± 16.58*
The parameters evaluated were ambulation and rearing frequencies and immobility
duration (s). Data are reported as means ± SEM.
*P<0.05 compared to the control (saline) group (ANOVA followed by the post hoc
Duncan test).
possibility of performing interesting studies
using knockout mice.
In mice, ambulation frequency was the
only behavior parameter able to detect dopa-
minergic supersensitivity, whereas previous
studies in rats have shown that withdrawal
from long-term haloperidol treatment not
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Figure 1. Effect of acute admin-
istration of buspirone (BUS) or
0.9% NaCl (SAL) on ambulation
frequency (A), rearing frequency
(B) and immobility duration (C)
of mice withdrawn from long-
term haloperidol (HAL - 2.5 mg/
kg) or SAL treatment (once daily,
for 20 days) and observed in an
open-field. The doses of buspi-
rone are reported as mg/kg.
*P<0.05 compared to SAL-SAL
group; +P<0.05 compared to
HAL-SAL group (ANOVA fol-
lowed by the post hoc Duncan
test).
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only increases ambulation and rearing fre-
quencies, but also decreases immobility du-
ration. This concern notwithstanding, it
should be noted that in those studies, ambu-
lation frequency was the most effective be-
havioral parameter in detecting dopaminer-
gic supersensitivity in rats (1,3,16). With
respect to the immobility duration param-
eter, a trend towards supersensitivity (de-
creased duration presented by the HAL-SAL
group when compared to the SAL-SAL
group) was observed, suggesting that the
phenomenon could be detected by this pa-
rameter in an experimental situation that
produced a stronger supersensitivity (for ex-
ample, if haloperidol treatment were more
prolonged). Indeed, the above-mentioned
trend was strengthened by the fact that acute
buspirone administration at the doses of 3.0
and 10 mg/kg (HAL-BUS3 and HAL-BUS10
groups, respectively) increased the immobil-
ity duration compared to the SAL-HAL group
but not compared to the SAL-SAL group.
However, there was no trend towards super-
sensitivity concerning rearing frequency data.
In this respect, Al-Khatib et al. (17) demon-
strated that the nucleus accumbens and cau-
date putamen have a differential role in me-
diating ambulation and rearing of rats in the
open-field test. Indeed, these investigators
showed that the caudate putamen seems to
play a greater role than the nucleus accum-
bens in the control of rearing. Species differ-
ences in the role of these two dopaminergic
regions in the control of rearing could be a
speculative hypothesis to explain the present
data.
The finding that acute buspirone admin-
istration abolishes the expression of dopa-
minergic supersensitivity measured by open-
field behavior extends previous studies which
have demonstrated that buspirone co-treat-
ment attenuated the development of dopa-
minergic supersensitivity (also measured by
this behavioral paradigm) in rats withdrawn
from haloperidol (12). Since buspirone shows
high affinity for dopaminergic- and seroto-
nergic-binding sites (10,18), it was suggested
that the inhibitory effect of repeated buspi-
rone co-treatment on the development of
behavioral supersensitivity could result from
peculiar actions of the drug on these two
neurotransmission systems. Specifically,
since buspirone seems to block preferen-
tially presynaptic dopamine receptors as com-
pared to the postsynaptic ones (19), it was
suggested that the ability of chronic buspi-
rone treatment to attenuate the development
of behavioral supersensitivity could be re-
lated to the development of presynaptic do-
pamine receptor supersensitivity (leading to
a decreased availability of dopamine in the
synaptic cleft). In line with this possibility,
while Tunnicliff et al. (20) showed that with-
drawal from repeated treatment with buspi-
rone led to marked reductions in the synthe-
sis of dopamine in the rat striatum, we have
shown that the drug potentiates yawning
behavior induced by small doses of apomor-
phine (16), which is considered a behavioral
parameter of nigrostriatal dopaminergic pre-
synaptic function (21). In addition, we have
demonstrated that withdrawal from long-
term haloperidol treatment at doses that se-
lectively block dopamine autoreceptors de-
creases open-field behavior, suggesting that
the development of dopamine autoreceptor
supersensitivity can attenuate the behavioral
effects produced by postsynaptic dopamine
receptor supersensitivity (22). Alternatively,
the inhibitory effects of chronic buspirone
on the development of behavioral dopamin-
ergic supersensitivity could be related to
modifications in the activity of 5-HT1a sero-
tonergic receptors since there is convincing
evidence that raphe serotonergic projections
inhibit dopamine nigrostriatal function (see
23).
Regardless of the exact mechanism by
which chronic buspirone attenuates the de-
velopment of behavioral dopaminergic su-
persensitivity, the inhibitory effect of acute
buspirone administration on the expression
of this behavioral phenomenon seems to be
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more probably related to the blockade of
dopamine postsynaptic receptors. Indeed, as
is the case for classical neuroleptics, acute
buspirone administration reduces apomor-
phine-induced stereotyped behavior (11),
which is thought to result from stimulation
of postsynaptic dopamine receptors (24). Ac-
cordingly, while the present study demon-
strates that the inhibitory effect of acute
buspirone on the open-field behavior is not
conditional upon prior haloperidol treatment,
acute administration of neuroleptic drugs
also inhibits spontaneous open-field behav-
ior, an effect that is thought to result from
blockade of postsynaptic dopamine recep-
tors (6). In line with these observations, the
symptoms of tardive dyskinesia are allevi-
ated by the administration of higher neuro-
leptic doses (25).
Although extrapolation to clinical situa-
tions from animal data must always be made
with caution, the present data, taken together
with previous behavioral results, suggest that
buspirone may alleviate tardive dyskinesia
symptoms, as well as attenuate the develop-
ment of this movement disorder.
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